

Novel Variant (*bla*_{VIM-11}) of the Metallo-β-Lactamase *bla*_{VIM} Family in a GES-1 Extended-Spectrum-β-Lactamase-Producing *Pseudomonas aeruginosa* Clinical Isolate in Argentina

Two major groups of acquired β-lactamases have emerged in *Pseudomonas aeruginosa*: Ambler class A extended-spectrum β-lactamases (ESBLs) and class B metallo-β-lactamases (MBLs) (7, 9). MBLs are an expanding group of carbapenemases that includes the VIM family. To date, multiple allelic variants, namely, VIM-1 to VIM-10 (<http://www.lahey.org/studies>), have been described in Europe, Asia, and the Americas, VIM-2 being the most ubiquitous enzyme by far (7, 8; R. E. Mendes, M. Castanheira, P. Garcia, M. Guzman, M. A. Toleman, T. R. Walsh, and R. N. Jones, Letter, Antimicrob. Agents Chemother. 48:1433–1434, 2004). Additionally, five types of ESBLs have been detected in *P. aeruginosa*: TEM, SHV, PER, VEB, and IBC/GES (9). Association between VIM and ESBLs still appears to be a rare event in *P. aeruginosa* and was reported only for VIM-2 with either PER-1 or IBC-2 (3; J. D. Docquier, J. D., F. Luzzaro, G. Amicosante, A. Toniolo, and G. M. Rossolini, Letter, Emerg. Infect. Dis. 7:910–911, 2001). MBL- or ESBL-producing *P. aeruginosa* isolates have not yet been reported in Argentina, while the coexistence of VIM with GES-1 in a single clinical isolate has not been documented anywhere.

In November 2002, after 8 days of meropenem treatment (120 mg/kg of body weight/day), *P. aeruginosa* M5109 was recovered as the sole isolate from the catheter of a 7-month-old patient at the Hospital de Niños “Ricardo Gutierrez.” The isolate was confirmed to be *P. aeruginosa* by using the API20NE system (bioMérieux, Marcy l’Etoile, France) and displayed uncommonly high levels of carbapenem resistance and synergism between imipenem- and zinc chelator-containing disks. Based on the antibiotype profile, colistin was added to the meropenem treatment, and the patient was discharged alive.

By susceptibility analysis carried out by agar dilution according to NCCLS guidelines (6), M5109 showed resistance to ticarcillin (MIC, 1,024 μg/ml), piperacillin (MIC, >1,024 μg/ml), piperacillin-tazobactam (MIC, 512 μg/ml), cefotaxime (MIC, 512 μg/ml), ceftazidime (MIC, 256 μg/ml), cefepime (MIC, 64 μg/ml), aztreonam (MIC, 32 μg/ml), imipenem (MIC, 512 μg/ml), meropenem (MIC, 128 μg/ml), amikacin (MIC, 256 μg/ml), gentamicin (MIC, >512 μg/ml), and ciprofloxacin (MIC, 32 μg/ml) but not to colistin (MIC, 0.5 μg/ml). The addition of 0.4 mM EDTA produced a ≥32-fold decrease in the carbapenem MICs. A carbapenemase was detected by a microbiological assay (4). Attempts to transfer ceftazidime or imipenem resistance by biparental conjugation (4) to *P. aeruginosa* ATCC 27853 were unsuccessful.

PCR screening of *bla* genes followed by DNA sequencing revealed the presence of *bla*_{TEM-1-like} (6), *bla*_{OXA-2-like} (1), *bla*_{GES-1-like} (primers used were GES-F [5′-GAAAAAGCA GCTCAGATCG] and GES-R [5′-CAACAACCCAATCTT TAGGA]), and *bla*_{VIM-2-like} (primers used were VIM-F and VIM-R [5]) (amplicons of 500, 480, 580, and 261 bp, respectively). Amplification for other ESBL (*bla*_{CTX-M-2}, *bla*_{PER}, and *bla*_{SHV} [4]) or MBL (*bla*_{SPM-1} and *bla*_{IMP} [unpublished data]) genes was negative. Since all the *bla*_{VIM} genes and most of the *bla*_{GES} genes presently reported are integron located (7, 9), we performed PCRs combining the primer 5′-CS, directed against

the 5′-conserved segment of class 1 integrons (4), with either VIM-R or GES-R, rendering amplicons of 475 and 819 bp, respectively. Thus, both *bla*_{VIM-2-like} and *bla*_{GES-1-like} were found as the first cassettes of different class 1 integrons in M5109. For further sequencing of these genes, additional reverse primers (VIM-Rb [5′-TGTTATGCCGCATCTGCCTG] and GES-Rc [5′-TCAACTATTTGTCCGTGCTC], respectively) were designed based on sequence alignments of highly related genes (Clustal X; <ftp://ftp-igbmc.u-strasbg.fr/pub/>). The 5′-CS-VIM-Rb amplicon (948 bp) contained an 801-bp-long open reading frame carrying the new *bla*_{VIM-11} allele, which differs from *bla*_{VIM-2} in a unique, nonsynonymous mutation and from *bla*_{VIM-3} or *bla*_{VIM-6} in another nonsilent change. Therefore, it may be considered an evolutionary intermediate between *bla*_{VIM-2} and *bla*_{VIM-3/6} (Fig. 1). The 1,008-bp-long 5′-CS-GES-Rc amplicon harbored an open reading frame of 864 bp that showed a unique silent change (C→T) at nucleotide position 591 relative to the *bla*_{GES-1} sequence.

By isoelectric focusing (4), only three bands at pI 5.4 (TEM-1), 5.8 (ESBL activity), and 7.85 (OXA-2-like) were visualized in M5109. A carbapenemase activity, inhibited in situ by EDTA (30 mM), was also detected at pI 5.8. Therefore, the




FIG. 1. Relatedness of *bla*_{VIM} genes. (A) Neighbor-joining tree of all the following *bla*_{VIM} genes reported to date (with GenBank accession numbers given in parentheses): *bla*_{VIM-1} (Y18050), *bla*_{VIM-2} (AF191564), *bla*_{VIM-3} (AF300454), *bla*_{VIM-4} (AY135661), *bla*_{VIM-5} (AY144612), *bla*_{VIM-6} (AY165025), *bla*_{VIM-7} (AJ536835), *bla*_{VIM-8} (AY524987), *bla*_{VIM-9} (AY524988), *bla*_{VIM-10} (AY524989), and *bla*_{VIM-11} (AY605049). (B) Substitutions in genes highly related to *bla*_{VIM-2}. The nucleotide positions of the indicated mutations (relative to the *bla*_{VIM-2} sequence) are shown. Amino acid changes and their positions based on the numbering system described by Galleni et al. (2) are indicated in parentheses.

coexistence of two β -lactamases at pI 5.8 (GES-1 and VIM-11) is proposed.

This is the first report of an MBL-mediated carbapenem-resistant and ESBL-producing *P. aeruginosa* isolate in Argentina and the first description anywhere of the coexistence of a VIM variant with GES-1 in a single strain. Our results, together with previous findings (M. Castanheira, R. E. Mendes, T. R. Walsh, A. C. Gales, and R. N. Jones, Letter, Antimicrob. Agents Chemother. 48:2344-2345, 2004; R. E. Mendes et al., letter, 2004), indicate that both VIM- and GES-producing *P. aeruginosa* strains have already become established in Latin America. The emergence of these enzymes in *P. aeruginosa* constitutes a public health concern in Argentina which requires efficient detection and brisk intervention to preserve antibiotic options.

REFERENCES

1. Bert, F., C. Branger, and N. Lambert-Zechovsky. 2002. Identification of PSE and OXA β -lactamase genes in *Pseudomonas aeruginosa* using PCR-restriction fragment length polymorphism. J. Antimicrob. Chemother. 50:11-18.
2. Galleni, M., J. Lamotte-Brasseur, G. M. Rossolini, J. Spencer, O. Dideberg, J.-M. Frère, and the Metallo- β -Lactamase Working Group. 2001. Standard numbering scheme for class B β -lactamases. Antimicrob. Agents Chemother. 45:660-663.
3. Mavroidi, A., E. Tzelepi, A. Tsakris, V. Miriagou, D. Sofianou, and L. S. Tzouvelekis. 2001. An integron-associated β -lactamase (IBC-2) from *Pseudomonas aeruginosa* is a variant of the extended-spectrum β -lactamase IBC-1. J. Antimicrob. Chemother. 48:627-630.
4. Melano, R., A. Corso, A. Petroni, D. Centrón, B. Orman, A. Pereyra, N. Moreno, and M. Galas. 2003. Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum β -lactamases in a *Klebsiella pneumoniae* clinical strain isolated in Argentina. J. Antimicrob. Chemother. 52:36-42.
5. Miriagou, V., E. Tzelepi, D. Gianneli, and L. S. Tzouvelekis. 2003. *Escherichia coli* with a self-transferable, multiresistant plasmid coding for metallo- β -lactamase VIM-1. Antimicrob. Agents Chemother. 47:395-397.
6. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Nordmann, P., and L. Poirel. 2002. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8:321-331.
8. Toleman, M. A., K. Rolston, R. N. Jones, and T. R. Walsh. 2004. *bla*_{VIM-7}, an evolutionarily distinct metallo- β -lactamase gene in a *Pseudomonas aeruginosa* isolate from the United States. Antimicrob. Agents Chemother. 48:329-332.
9. Weldhagen, G. F., L. Poirel, and P. Nordmann. 2003. Ambler class A extended-spectrum β -lactamases in *Pseudomonas aeruginosa*: novel developments and clinical impact. Antimicrob. Agents Chemother. 47:2385-2392.

Fernando Pasteran

Diego Faccone

Alejandro Petroni

Melina Rapoport

Marcelo Galas*

Servicio Antimicrobianos

Departamento Bacteriología

Instituto Nacional de Enfermedades Infecciosas-ANLIS

"Dr. Carlos G. Malbrán"

Ciudad Autónoma de Buenos Aires, Argentina

Miryam Vázquez

Adriana Procopio

Sección Microbiología

Hospital de Niños "Dr. Ricardo Gutiérrez"

Gobierno de Buenos Aires

Ciudad Autónoma de Buenos Aires, Argentina

*Phone and fax: 54 11 4 303 2812

E-mail: mgalas@anlis.gov.ar